Effects of HIV status and antiretroviral therapy on blood pressure

HIV Medicine

Volumn 10, Issue 6, 2009, Pages 388-394

  Wilson, Sarah L ^a   Scullard, G ^b   Fidler, S J ^a   Weber, J N ^a   Poulter, N R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Antiretroviral therapy; Blood pressure; Epidemiology; HAART; HIV

Indexed keywords

CHOLESTEROL; CREATININE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LONDON; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 67449146277     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00699.x     Document Type: Article

References (23)

1. Palella FJ Jr, Delaney KM and the HIV Outpatient Study Investigators et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998; 338: 853-860.
2. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort Study. Eur J Med Res 2000; 5: 329-333.
3. Bonnet F, Morlat P, Chene G et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med 2002; 3: 195-199.
4. Gazzaruso C, Bruno R, Garzaniti A et al. Hypertension among HIV patients: Prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21: 1377-1382.
5. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: Results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Disease 2003; 22: 731-736.
6. Mattana J, Siegal FP, Sankaran RT, Singhal PC. Absence of age-related increase in systolic blood pressure in ambulatory patients with HIV infection. Am J Med Sci 1999; 317: 232-237.
7. Jerico C, Knobel H, Montero M et al. Hypertension in HIV-infected patients: Prevalence and related factors. Am J Hypertens 2005; 18: 1396-1401.
8. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20: 1019-1026.
9. Palacios R, Santos J, Garcia A et al. Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naïve patients. HIV Med 2006; 7: 10-15.
10. Sterne JAC, May M, Bucher HC et al for the Swiss HIV Cohort Study. HAART and the heart: Changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Int Med 2007; 261: 255-267.
11. Chow DC, Souza SA, Richmond-Crum SM, Shikuma C. Epidemiological evidence of increasing blood pressure in HIV-1-infected individuals in the era of HAART. Antiviral Ther 2000; 5: 31.
12. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2003; 4: 411-416.
13. Seaburg EC, Munoz A, Lu M et al. for the Mulicenter AIDS Cohort Study (MACS). Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19: 953-960.
14. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A for the DAD Study Group. Cardiovascular disease risk factors in HIV patients -association with antiretroviral therapy. Results from the DAD Study. AIDS 2003; 17: 1179-1193.
15. Thiebaut R, El-Sadr WM, Friis-Moller N, Rickenbach M, Reiss P, D'Arminio Monforte A for the Data Collection of Adverse Events of Anti-HIV Drugs (DAD) Study Group. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antiviral Ther 2005; 10: 811-823.
16. B Gazzard on behalf of the British HIV Association Writing Committee. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
17. The World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th World Medical Association General Assembly, Helsinki Finland June 1964, last amended by the World Medical Association General Assembly in Tokyo 2004. Available at http://www.wma.net accessed 2 August 2005.
18. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline for Good Clinical Practice E6(R1) Current Step 4 Version, 10 June 1996. Available at http://www.ich.org accessed 2 August 2005.
19. Blood Pressure Measurement Guidelines. British Hypertension Society. Available at http://www.hyp.ac.uk/bhs accessed on 21 February 2005.
20. Department of Health. Annual Report to the European Monitoring Centre for Drugs and Drug Addiction (EMC DDA). London: Home Office, 2006.
21. Allender S, Peto V, Scarborough P, Boxer A, Rayner M. Coronary Heart Disease Statistics 2007. London: British Heart Foundation, 2007.
22. McCarron P, Davey Smith G, Okasha M, McEwen J. Blood pressure in young adulthood and mortality from cardiovascular disease. Lancet 2000; 355: 1430-1431.
23. The SPARTAC Trial. Available at http://www.ctu.mrc.ac.uk/studies/ spartac.asp accessed on 5 September 2008.